HORSHOLM, Denmark, Feb. 9, 2012 /PRNewswire/ -- William J. Polvino M.D president and CEO of Veloxis Pharmaceuticals A/S, will present at the 14th Annual BIO CEO & Investor Conference at 3 p.m. EST, Tuesday, Feb. 14, at TheWaldorf-Astoria in New York. Dr. Polvino will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro', Veloxis' candidate to prevent organ transplant rejection.
About Veloxis Pharmaceuticals A/S
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro', for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development.
For further information, please visit www.veloxis.com.
For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S
(732) 321-3208
jdw@veloxis.com
SOURCE Veloxis Pharmaceuticals A/S
